'It's a fine balance': CFOs struggle to manage GLP-1 access and costs
The skyrocketing demand for GLP-1 drugs, initially developed for diabetes but now widely used for weight loss, is putting increasing financial strain on health plans and providers.
The skyrocketing demand for GLP-1 drugs, initially developed for diabetes but now widely used for weight loss, is putting increasing financial strain on health plans and providers.
